Correlated with day 28 counts of CD3+ T cells (R = 20.47, P,0.001; Figure

Correlated with day 28 Pentagastrin price counts of CD3+ T cells (R = 20.47, P,0.001; Figure 2A), CD8+ T cells (R = 20.41, P = 0.002), CD4+ T cells (R = 20.39, P = 0.002), ?naive CD4+ T cells (R = 20.40, P = 0.002), and memory CD4+ T cells (R = 20.38, P = 0.004), but not with counts of NK/T cells (R = 20.17, P = 0.2), nor NK cells (R = 20.02, P = 0.9), nor with day-28 donor T cell chimerism levels (R = 0.0, P = 0.95). There was no significant association either between day 28 IL-7 and IL15 levels (R = 0.07, P = 0.6). Further, day 28 IL-15 levels correlated with day 28 counts of NK cells (R = 20.32, P = 0.015; Figure 2B) but not with those of T cell subsets, nor with day-28 donor 12926553 T cell chimerism levels (R = 0.14, P = 0.29). To further assess the potential association between early IL-7 or IL-15 levels on immune recovery, we analysed whether there was a relationship between median cytokine levels on days 7 and 14 and the difference of lymphocyte subset counts between days 80?100 (median) and days 14?8 (median). Interestingly, in multivariate analyses, early IL-7 levels did not correlate with any Table 2. Multivariable analyses of factors affecting cytokines levels on days 7 and 14 after allo-HSCT.Factor(s) associated with higher levels*,{ IL-7 – Low ALC on day 7 or 14 (P,0.001). – Low # of transplanted T cells (CD3+) (P = 0.001). – High CRP levels on day 7 or 14 (P = 0.033). – Unrelated donors (P = 0.006). – High donor age (P = 0.003). IL-15 – 4 vs 2 Gy TBI (P = 0.002). – Unrelated donors (P = 0.001). – High CRP levels on day 7 or 14 (P = 0.006). – Low ALC on day 7 or 14 (P,0.001). *Other factors assessed were number of days after allo-HSCT, patient age, and mesenchymal stromal cells infusion or not; { P values were determined according to generalized linear mixed models; TBI, total body irradiation. doi:10.1371/journal.pone.0055876.tFigure 2. Correlation between CD3+ T cell counts and IL-7 levels on day 14 (black circles and continuous line) and on day 28 (open triangles and broken lines) after transplantation (A). Correlation between NK cell counts and IL-15 levels on day 14 (black circles and continuous line) and on day 28 (open triangles and broken lines) after transplantation (B). doi:10.1371/journal.pone.0055876.glymphocyte subset increment from days 14?8 to day 80?00 after transplantation, while high IL-15 levels early after transplantation correlated with a lower increment of NK cells over time (P = 0.04).IL-7 and IL-15 Levels did not Predict for Subsequent Acute GVHDThe 180-day cumulative incidence of grade II V acute GVHD was 30 , a rate similar to what has been observed by other group of investigators using similar SMER 28 price conditioning regimen [45]. As shown in the Figure 3, no statistically significant association between cytokines levels 15755315 on days 7 or 14 after transplantation and occurrence of grade II V acute GVHD were observed. Specifically, the 180-day cumulative incidence of grade II V acute GVHD was 29 in patients with day 7 IL-7 levels.median (5.1 pg/mL) versus 20 in patients with day 7 IL-7 levels # median (P = 0.38) (Figure 3A). Similarly, the 180-day cumulativeIL-7 and IL-15 after Allo-HSCTFigure 3. Cumulative incidence of grade II V acute GVHD according to day 7 IL-7 plasma levels among nonmyeloablative recipients (P = 0.4) (A). Cumulative incidence of grade II V acute GVHD according to day 14 IL-7 plasma levels among nonmyeloablative recipients (P = 0.18) (B). Cumulative incidence of grade II V acute GVHD according to day 7 IL-15 serum lev.Correlated with day 28 counts of CD3+ T cells (R = 20.47, P,0.001; Figure 2A), CD8+ T cells (R = 20.41, P = 0.002), CD4+ T cells (R = 20.39, P = 0.002), ?naive CD4+ T cells (R = 20.40, P = 0.002), and memory CD4+ T cells (R = 20.38, P = 0.004), but not with counts of NK/T cells (R = 20.17, P = 0.2), nor NK cells (R = 20.02, P = 0.9), nor with day-28 donor T cell chimerism levels (R = 0.0, P = 0.95). There was no significant association either between day 28 IL-7 and IL15 levels (R = 0.07, P = 0.6). Further, day 28 IL-15 levels correlated with day 28 counts of NK cells (R = 20.32, P = 0.015; Figure 2B) but not with those of T cell subsets, nor with day-28 donor 12926553 T cell chimerism levels (R = 0.14, P = 0.29). To further assess the potential association between early IL-7 or IL-15 levels on immune recovery, we analysed whether there was a relationship between median cytokine levels on days 7 and 14 and the difference of lymphocyte subset counts between days 80?100 (median) and days 14?8 (median). Interestingly, in multivariate analyses, early IL-7 levels did not correlate with any Table 2. Multivariable analyses of factors affecting cytokines levels on days 7 and 14 after allo-HSCT.Factor(s) associated with higher levels*,{ IL-7 – Low ALC on day 7 or 14 (P,0.001). – Low # of transplanted T cells (CD3+) (P = 0.001). – High CRP levels on day 7 or 14 (P = 0.033). – Unrelated donors (P = 0.006). – High donor age (P = 0.003). IL-15 – 4 vs 2 Gy TBI (P = 0.002). – Unrelated donors (P = 0.001). – High CRP levels on day 7 or 14 (P = 0.006). – Low ALC on day 7 or 14 (P,0.001). *Other factors assessed were number of days after allo-HSCT, patient age, and mesenchymal stromal cells infusion or not; { P values were determined according to generalized linear mixed models; TBI, total body irradiation. doi:10.1371/journal.pone.0055876.tFigure 2. Correlation between CD3+ T cell counts and IL-7 levels on day 14 (black circles and continuous line) and on day 28 (open triangles and broken lines) after transplantation (A). Correlation between NK cell counts and IL-15 levels on day 14 (black circles and continuous line) and on day 28 (open triangles and broken lines) after transplantation (B). doi:10.1371/journal.pone.0055876.glymphocyte subset increment from days 14?8 to day 80?00 after transplantation, while high IL-15 levels early after transplantation correlated with a lower increment of NK cells over time (P = 0.04).IL-7 and IL-15 Levels did not Predict for Subsequent Acute GVHDThe 180-day cumulative incidence of grade II V acute GVHD was 30 , a rate similar to what has been observed by other group of investigators using similar conditioning regimen [45]. As shown in the Figure 3, no statistically significant association between cytokines levels 15755315 on days 7 or 14 after transplantation and occurrence of grade II V acute GVHD were observed. Specifically, the 180-day cumulative incidence of grade II V acute GVHD was 29 in patients with day 7 IL-7 levels.median (5.1 pg/mL) versus 20 in patients with day 7 IL-7 levels # median (P = 0.38) (Figure 3A). Similarly, the 180-day cumulativeIL-7 and IL-15 after Allo-HSCTFigure 3. Cumulative incidence of grade II V acute GVHD according to day 7 IL-7 plasma levels among nonmyeloablative recipients (P = 0.4) (A). Cumulative incidence of grade II V acute GVHD according to day 14 IL-7 plasma levels among nonmyeloablative recipients (P = 0.18) (B). Cumulative incidence of grade II V acute GVHD according to day 7 IL-15 serum lev.